Eli Lilly has agreed to acquire Merida Biosciences for as much as $2.875 billion in cash, securing a biotechnology platform designed to remove disease-causing antibodies without broadly suppressing the immune system. The transaction adds another early-stage immunology bet to Lilly’s research portfolio as large drugmakers compete for treatments that intervene closer to the biological cause of autoimmune disease.
The announced price includes an upfront payment and additional cash tied to development or commercial milestones. Lilly and Merida did not break out the size of each component in their public statement. The companies expect the transaction to close in the fourth quarter of 2026, subject to regulatory approval and other customary conditions.
Targeting harmful antibodies
Merida is developing biologic medicines intended to selectively degrade pathogenic autoantibodies. These antibodies can mistakenly attack the body’s own tissues and drive a range of autoimmune and allergic conditions. Many existing therapies reduce immune activity more broadly, which can control disease but may also interfere with useful immune functions. Merida’s approach is designed to distinguish the harmful antibodies and remove them more precisely.
Its lead program, MER511, is being studied for Graves’ disease and thyroid eye disease. Graves’ disease is caused by antibodies that stimulate the thyroid receptor, producing excessive thyroid activity and, in some patients, inflammation affecting tissue around the eyes. Lilly said initial Phase 1 results showed substantial reductions in the pathogenic thyroid-stimulating antibodies while maintaining what the companies described as a favorable early safety profile.
Those findings are preliminary. Phase 1 studies are principally designed to evaluate safety and dosing, and early biomarker changes do not establish that a medicine will ultimately improve symptoms or receive regulatory approval. Further trials will be needed to define the durability of the antibody reductions, the effect on patients and the risks of treatment.
A platform acquisition
The attraction for Lilly goes beyond a single candidate. The drugmaker says the same antibody-engineering method could potentially be applied to other diseases in which identifiable autoantibodies are central to the pathology. Buying Merida gives Lilly ownership of the platform, its current programs and the scientific team developing them.
For Merida, joining a global pharmaceutical company provides greater clinical-development and manufacturing resources. For Lilly, the milestone-heavy payment structure links a portion of the purchase price to future progress, limiting how much is paid before the programs reach specified goals. The full $2.875 billion figure should therefore be understood as the maximum potential consideration, not necessarily the amount transferred at closing.
The deal continues an active period of investment across immunology, where companies are pursuing medicines that are more selective than conventional immune suppression. Antibody degradation is one of several emerging strategies intended to produce deeper or longer-lasting control by removing a disease driver rather than only blocking its downstream effects.
Lilly’s next task will be to move Merida’s research through larger and more demanding clinical studies. If the precision approach works as intended, it could open a path into multiple antibody-mediated diseases. If later trials fail to confirm the early biological signals, the contingent structure means part of the headline acquisition value may never be paid. For now, the agreement is a significant endorsement of the science, but not yet proof of an approved therapy.
